Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.79% | -42.44% | 143.77% | 24,160.00% | 1,129.07% |
| Total Depreciation and Amortization | 49.23% | -76.83% | -3.47% | -5.31% | -9.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4,692.86% | 100.37% | 110.86% | 26.65% | -104.61% |
| Change in Net Operating Assets | -290.94% | -171.79% | -697.22% | -134.30% | 516.95% |
| Cash from Operations | -115.15% | -92.09% | 5.64% | 573.48% | 2,572.20% |
| Capital Expenditure | -90.63% | -46.38% | 41.46% | -1,025.00% | 21.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16,490.63% | -46.38% | -14.29% | -1,025.00% | 21.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00% | 0.00% | -50.00% | 0.00% |
| Issuance of Common Stock | -96.44% | -93.99% | -85.43% | 527.42% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -683.33% | -34.15% | -- | -- | 45.45% |
| Cash from Financing | -173.75% | -102.13% | -85.76% | 528.02% | 22,278.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.93% | -95.94% | -15.44% | 1,418.13% | 4,465.00% |